These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 20214696

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS.
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
    Xu XJ, Ma DD, Lv F, Wang JY, Liu Y, Xia WB, Jiang Y, Wang O, Xing XP, Yu W, Li M.
    Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
    [Abstract] [Full Text] [Related]

  • 7. A multicenter randomized double-masked comparative study of different preparations of alendronate in osteoporosis - monthly (four weeks) intravenous versus once weekly oral administrations.
    Shiraki M, Nakamura T, Fukunaga M, Sone T, Usami A, Inoue T.
    Curr Med Res Opin; 2012 Aug; 28(8):1357-67. PubMed ID: 22769235
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB.
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [Abstract] [Full Text] [Related]

  • 10. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
    Devogelaer JP, Sambrook P, Reid DM, Goemaere S, Ish-Shalom S, Collette J, Su G, Bucci-Rechtweg C, Papanastasiou P, Reginster JY.
    Rheumatology (Oxford); 2013 Jun; 52(6):1058-69. PubMed ID: 23365149
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Zoledronic acid infusion for lumbar interbody fusion in osteoporosis.
    Tu CW, Huang KF, Hsu HT, Li HY, Yang SS, Chen YC.
    J Surg Res; 2014 Nov; 192(1):112-6. PubMed ID: 24948545
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
    Tutaworn T, Nieves JW, Wang Z, Levin JE, Yoo JE, Lane JM.
    Osteoporos Int; 2023 Mar; 34(3):573-584. PubMed ID: 36602607
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.